BIA
HZNP

Bell Investment Advisors’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Bell Investment Advisors’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-150
Closed -$17.4K – 2038
2023
Q3 		$17.4K Sell
150
-4
-3% -$430 ﹤0.01% 350
2023
Q2 		$15.8K Sell
154
-8
-5% -$844 ﹤0.01% 359
2023
Q1 		$17.7K Sell
162
-7
-4% -$774 ﹤0.01% 331
2022
Q4 		$19.2K Buy
169
+90
+114% +$7.47K ﹤0.01% 313
2022
Q3 		$5K Buy
79
+24
+44% +$1.68K ﹤0.01% 739
2022
Q2 		$4K Buy
+55
New +$5.21K ﹤0.01% 886
2021
Q4 		$8K Sell
76
-5
-6% -$545 ﹤0.01% 585
2021
Q3 		$9K Buy
+81
New +$8.41K ﹤0.01% 502

Other funds holding HZNP

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
VWA
Valued Wealth Advisors Holladay, Utah $275M AUM 24.94% 1-Year Est. Return
FSWA
Financial Synergies Wealth Advisors Houston, Texas $1.18B AUM 31.41% 1-Year Est. Return
BCMLT
Beacon Capital Management LLC (Tennessee) Franklin, Tennessee $683M AUM 22.58% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Bell Investment Advisors's HZNP Position: Q4 2023 in Review

Bell Investment Advisors sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2023, closing a stake of 150 shares — an estimated $17.4K sold.

Bell Investment Advisors first reported a position in HZNP in Q3 2021 and held it in 8 quarters. The position peaked at $19.2K in Q4 2022. 6 funds tracked by Wall St. Rank hold HZNP as of Q4 2023.

  • Bell Investment Advisors reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2023 after selling out during the quarter.
  • Bell Investment Advisors sold 150 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2023, an estimated $17.4K.
  • Bell Investment Advisors first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q3 2021 and held it in 8 quarters.
  • Bell Investment Advisors's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $19.2K in Q4 2022.
  • 6 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2023.

Based on Bell Investment Advisors's 13F filing for Q4 2023, filed 14 Feb 2024.